Biogen’s Q2 Highlights Need For Near-Term Successes
Executive Summary
Second quarter performance was better than expected, but commercial weaknesses show the need for R&D wins and M&A deals as Tecfidera generics and aducanumab uncertainty weigh on the company.
You may also be interested in...
BrainStorm's Cell Therapy Disappoints In Phase III ALS Study
Top-line results from BrainStorm’s NurOwn Phase III ALS study show the cell therapy missed the primary efficacy endpoint, but clinically meaningful responses were seen in a pre-specified subgroup which investigators considered potentially a significant step forward in therapy.
Roche’s Evrysdi Approved For SMA, Priced Below Competitors
Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma.
One Way To Get Ahead: Biogen To Test Spinraza Given After Novartis’s Zolgensma
Biogen said some spinal muscular atrophy patients are currently being treated with Spinraza after receiving the Novartis gene therapy – its main competitor – so it will start a study of the risk/benefit in 2021.